Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress.
Doose syndrome, otherwise traditionally known as myoclonic-astatic epilepsy, was first described as a unique epilepsy syndrome by Dr Hermann Doose in 1970. In 1989, the International League Against Epilepsy classified it formally as a symptomatic generalized epilepsy, and 20 years later it was renamed 'epilepsy with myoclonic-atonic seizures'. In this review, we discuss the components of this unique disorder including its incidence, clinical features, and electroencephalographic findings. Recent evidence has suggested possible genetic links to the GEFS+ (generalized epilepsy with febrile seizures plus) family, and, additionally, some children with structural brain lesions can mimic the Doose syndrome phenotype. Treatment strategies such as corticosteroids, ethosuximide, and valproate have been described as only partially effective, but newer anticonvulsants, such as levetiracetam and zonisamide, may provide additional seizure control. The most effective treatment reported to date appears to be the ketogenic diet. Prognosis is quite varied in this disorder; however, many children can have a remarkably normal neurodevelopmental outcome.
Kelley
Sarah A
SA
Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Kossoff
Eric H
EH
D000927:Anticonvulsants / Q000627:therapeutic use*; D004569:Electroencephalography; D004831:Epilepsies, Myoclonic / Q000235:genetics / Q000266:history / Q000628:therapy; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009154:Mutation / Q000235:genetics; D062558:NAV1.9 Voltage-Gated Sodium Channel; D009479:Neuropeptides / Q000235:genetics; D011379:Prognosis; D011963:Receptors, GABA-A / Q000235:genetics; D015222:Sodium Channels / Q000235:genetics
D000927:Anticonvulsants; C546279:GABRG2 protein, human; D062558:NAV1.9 Voltage-Gated Sodium Channel; D009479:Neuropeptides; D011963:Receptors, GABA-A; C491886:SCN11A protein, human; D015222:Sodium Channels